U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H40O15
Molecular Weight 676.6617
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ICARIIN

SMILES

COC1=CC=C(C=C1)C2=C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)C(=O)C4=C(O2)C(CC=C(C)C)=C(O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C=C4O

InChI

InChIKey=TZJALUIVHRYQQB-XLRXWWTNSA-N
InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32-,33+/m0/s1

HIDE SMILES / InChI
Icariin is a naturally occurring compound isolatable from several plant species within the genus Epimedium which is mostly endemic to China. Plant extracts containing icarrin have been used in traditional Chinese medicine as aphrodisiacs and to treat erectile dysfunction. Icariin has been investigated in humans as a treatment method for bipolar disorder and alcohol or cocaine abuse (Phase III). For the treatment of impotence, icariin has been shown to be a weak PDE5 inhibitor capable of enhancing the production of nitric oxide. Also related to PDE5 activity icarrin has been investigated as a potential treatment in mouse models of Alzheimer's disease. Icariin is sold worldwide as an over-the-counter medication for sexual performance, athletic performance, and other health benefits (it improves memory function, protects from osteoporosis, etc).

CNS Activity

Curator's Comment: Known to be CNS active in mice. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O76074
Gene ID: 8654.0
Gene Symbol: PDE5A
Target Organism: Homo sapiens (Human)
5.9 µM [IC50]
Target ID: P56818
Gene ID: 23821.0
Gene Symbol: Bace1
Target Organism: Mus musculus (Mouse)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Icariin 60

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Icariin 60

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Simple and sensitive liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of five Epimedium prenylflavonoids in rat sera.
2009-01-01
Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells.
2008-11-14
[Effect of icariin on intermediate and advanced activation of murine T lymphocytes in vitro].
2008-11
[Primary study on effect of various components of modified formula radix hedysari on peripheral nerve regeneration].
2008-09
Potent inhibition of human phosphodiesterase-5 by icariin derivatives.
2008-09
Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo).
2008-09
Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro.
2008-08
Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula.
2008-07-23
Fast quality control of Herba Epimedii by using Fourier transform infrared spectroscopy.
2008-07
Chemical markers for the quality control of herbal medicines: an overview.
2008-06-28
Determination of icariin in rat plasma by reverse-phase high-performance liquid chromatography after oral administration of a lipid-based suspension of Epimedium koreanum extract.
2008-06
Involvement of NF-kappaB and AP-1 activation in icariin promoted cardiac differentiation of mouse embryonic stem cells.
2008-05-31
Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2-dependent manner.
2008-05-02
[Absorption mechanism of icariin across Caco-2 monolayer model].
2008-05
Effects of icariin combined with Panax notoginseng saponins on ischemia reperfusion-induced cognitive impairments related with oxidative stress and CA1 of hippocampal neurons in rat.
2008-05
Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells.
2008-04-01
Simultaneous extraction of epimedin A, B, C and icariin from Herba Epimedii by ultrasonic technique.
2008-04
Simultaneous determination of seven flavonoids in Epimedium using pressurized liquid extraction and capillary electrochromatography.
2008-03
A rapid method for simultaneous determination of 15 flavonoids in Epimedium using pressurized liquid extraction and ultra-performance liquid chromatography.
2008-01-22
Statistically designed enzymatic hydrolysis for optimized production of icariside II as a novel melanogenesis inhibitor.
2008-01
Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure.
2008-01
Effects of total flavonoids and flavonol glycosides from Epimedium koreanum Nakai on the proliferation and differentiation of primary osteoblasts.
2008-01
Trace analysis of icariin in human serum with dansyl chloride derivatization after oral administration of Epimedium decoction by liquid chromatography tandem mass spectrometry.
2007-12-15
Effect of lipid-based suspension of Epimedium koreanum Nakai extract on sexual behavior in rats.
2007-12-03
Simultaneous determination of icariin, icariside II and osthole in rat plasma after oral administration of the extract of Gushudan (a Chinese compound formulation) by LC-MS/MS.
2007-12-01
Protective effect of icariin on DNA against radical-induced oxidative damage.
2007-12
Simultaneous determination of nine flavonoids and qualitative evaluation of Herba Epimedii by high performance liquid chromatography with ultraviolet detection.
2007-12
LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma.
2007-11-30
[Systematic studies on quality of main species of Herba epimedii].
2007-11
[Effects of Erxian Decoction and its separate prescriptions on the levels of luteinizing hormone and follicle-stimulating hormone in anterior pituitary cells from female rats].
2007-11
Icariin enhances the osteogenic differentiation of bone marrow stromal cells but has no effects on the differentiation of newborn calvarial osteoblasts of rats.
2007-10
Pharmacological activity of cardiovascular agents from herbal medicine.
2007-10
Icariin promotes expression of PGC-1alpha, PPARalpha, and NRF-1 during cardiomyocyte differentiation of murine embryonic stem cells in vitro.
2007-10
Simultaneous quantitation of five flavonoid glycosides in Herba Epimedii by high-performance liquid chromatography-tandem mass spectrometry.
2007-09-20
Simultaneous determination of 15 flavonoids in Epimedium using pressurized liquid extraction and high-performance liquid chromatography.
2007-09-07
[Research on quality of Epimedium extract in market].
2007-09
Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro.
2007-08-16
[HPLC-MS3 analysis of chemical constituents in Epimedium brevicornum].
2007-08
Hypouricemic action of selected flavonoids in mice: structure-activity relationships.
2007-08
Protective effects of icariin against learning and memory deficits induced by aluminium in rats.
2007-08
Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro.
2007-07
HPLC analysis and pharmacokinetics of icariin in rats.
2007-06
Chemical constituents of roots of Epimedium wushanense and evaluation of their biological activities.
2007-06
Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture.
2007-05
Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats.
2007-05
[Comparison of antioxidative and antitumor activities of six flavonoids from Epimedium koreanum].
2007-04
Vasorelaxant effects of icariin on isolated canine coronary artery.
2007-04
[A review on research of raw material and cut crude drug of Herba epimedii in last ten years].
2007-03
Comparison between HPLC and HPTLC densitometry for the determination of icariin from Epimedium koreanum extracts.
2007-03
[Effect of er xian decoction and its subdivisions on granulosa cells secretory function in rats].
2006-06
Patents

Sample Use Guides

In an open-label pilot trial, adults with current bipolar disorder and current cocaine or alcohol use disorders were treated with 100 mg/day icariin. After 3 weeks patients who had less than 30% reduction in the Hamilton Rating Scale for Depression or still abusing substances were titrated up to a dose of 200 mg/day. At week 6 patients who had less than 50% reduction in HAMD score continued to abuse alcohol/cocaine were titrated up to a maximum dose of 300 mg/day.
Route of Administration: Oral
Isolated segments of rabbit corpus cavernosum were exposed to increasing concentrations of icariin while the accumulation of cGMP and cAMP was monitored by means of a 1251 radioimmunoassay. Icariin increased accumulated cGMP and cAMP in a dose-dependent manner. An EC50 of 4.62 uM was determined for icariin, which was contrasted to an EC50 of 0.42 uM for Sildenafil under similar conditions.
Name Type Language
ICARIIN
Common Name English
EPIMEDII HERBA ICARIIN [MI]
Preferred Name English
4H-1-BENZOPYRAN-4-ONE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-7-(.BETA.-D-GLUCOPYRANOSYLOXY)-5-HYDROXY-2-(4-METHOXYPHENYL)-8-(3-METHYL-2-BUTEN-1-YL)-
Systematic Name English
Classification Tree Code System Code
DSLD 1125 (Number of products:24)
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
Code System Code Type Description
SMS_ID
100000168995
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
RXCUI
1788871
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
WIKIPEDIA
ICARIIN
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
PUBCHEM
5318997
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
MERCK INDEX
m4942
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY Merck Index
FDA UNII
VNM47R2QSQ
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
DAILYMED
VNM47R2QSQ
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
DRUG BANK
DB12052
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
EPA CompTox
DTXSID00964133
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
CAS
489-32-7
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY
EVMPD
SUB182587
Created by admin on Mon Mar 31 19:02:01 GMT 2025 , Edited by admin on Mon Mar 31 19:02:01 GMT 2025
PRIMARY